OR WAIT null SECS
Japan is increasingly a region where opportunities for global registration studies abound, supported by government policies as well as the medical community and its local population. However, incorporating Japan as an integral part of your global trial execution strategy does not come without its unique challenges.
Insights for Pharma Executives Sourcing Global Clinical Trials in the U.S. and Japan
The Japanese pharmaceutical market is the world’s second largest behind the U.S., representing 9.7% of the world pharma market in 2013, with sales estimated at $115 billion. According to Deloitte, the industry’s annual average growth rate of 2.2% is expected through to 2018, with revenues totaling $128 billion. Though a highly attractive market, historically Japan has been insular-a consequence of a number of factors, such as medical culture and the complexity of the underlying regulatory context. One of the nuances of this environment was the so-called “drug-lag,” where new drug approvals could lag up to six years behind U.S. and European Union (EU) approval. Because of these delays, companies often didn’t bother to pursue drug development. The end result was that Japanese patients had to wait years, or sometimes decades, to get the same drugs that were available in the U.S., Europe, and elsewhere. With the advance of modern communication and open access to information, problems associated with drug lag became apparent in Japanese society, and change soon followed. In 2007, the Japanese Ministry of Health, Labor and Welfare (MHLW) reversed some key policies, which, in turn, led to markedly reduced regulatory review periods and a friendlier environment for global trials. In many ways, the Japanese clinical research landscape has shifted. Once viewed as unique and difficult to work with, Japan is increasingly a region where opportunities for global registration studies abound, supported by government policies as well as the medical community and its local population.
Incorporating Japan as an integral part of your global trial execution strategy does not come without its unique challenges. While opportunities are on the rise for those life sciences companies eager to enter the Japanese pharma market, cultural differences and socioeconomic factors have a significant impact on the outcome of those business engagements. Given the importance of the Japanese market and its renewed interest in participating in global studies, it is more important than ever to understand how such factors may impact global study participation and execution, as well as the technologies used to support clinical research.
On the flip side, Japanese companies eager to engage in global clinical studies and work with partners in the U.S. and beyond face their own set of challenges when it comes to understanding key cultural and societal differences which manifest in various forms, such as technology practices, patient recruitment, and even study design.
Culture shock, the personal disorientation a person may feel when experiencing an unfamiliar way of life, is normal when doing business in Japan. “Stumbling seven times but recovering eight” is the literal translation of the Japanese proverb, nanakorobi yaoki, meaning that “perseverance is better than defeat”; faux pas are expected, but with the right preparation and observance of Japan’s culture’s etiquette and understanding of clinical research conduct subtilties, these mistakes can be mitigated. Sophistication and worldliness elements signal executive presence, creating a favorable impression of them and, by extension, their business.
So how do you set your company up for success?
Aligning studies with Japanese medical practice is important in order to increase study participation and patient engagement, which ultimately helps to get medicines to patients in sooner. Aspects of the healthcare system, norms for technology platforms, as well as patient incentives, carry slight differences that can translate into major barriers if not understood and managed well from the outset. The following are representative aspects of the clinical research environment in Japan, which should be considered when designing global studies for Japanese investigators and patients.
In Japan, the use of electronic medical records (EMRs) is more standard practice than in the West, making searching for trial participants easier for investigators. This highlights how Japan can help US companies drive digital innovation in trial operations.
Ultimately, communication occurs between human beings and not between cultures, and when in doubt, it pays to err on the side of conservatism. With this in mind, it’s important to consider the following matters of cultural etiquette if you’re doing business with Japanese pharma (or are hoping to win one as a client) – Eight key ways to prepare yourself for the culture differences:
As previously noted, EMRs are more prevalent in Japan, which presents increased opportunities for patient recruitment and engagement. But there are complexities due to the fact that various EMR systems were designed and implemented by different vendors. This means that the hospital information systems in Japan typically only operate together through the integration of different platforms, which may be difficult outside of regional networks.1 Though there are challenges, there are also emerging opportunities for clinical research. In 2010, Japan launched the National Clinical Database (NCD), which is a prospective registry linked to various types of board certification systems regarding surgery. When linked to cancer registries, the NCD has great potential for impacting patient care. Collaboration between Japan and the U.S. has recently started and is expected to provide global benchmarking and enable a valuable comparison of cancer treatments.
The Japanese pharma industry is increasingly opening up to foreign markets, having become a popular destination for multi-regional clinical trials (MRCTs) since 2006, when bridging studies-studies to determine whether foreign trial results are applicable to patients in Japan-were allowed to be included in MRCTs, decreasing the time and expense involved in getting new drugs to Japanese patients.
As clinical trials continue to grow in size and complexity, more and more companies are adopting software-as-a-service (SaaS) applications to manage data and streamline electronic data capture (EDC), study start-up, and monitoring workflows. Particularly in the context of MRCTs, technologies such as interactive voice response (IRT) and electronic patient-reported data sources (ePRO) are becoming more commonplace. These trends underscore the need for Japanese pharma to understand how practices in the U.S. influence clinical research software in global implementations.
Japanese pharma executives will find that business practices at home do not necessary translate into a winning combination in America. Understanding some of the common business practices used in U.S. life sciences companies will help ease frustrations these organizations may feel when dealing with U.S.-based partners.
From a westerner’s viewpoint, a business meeting is a place to discuss issues, with the clear goal of reaching conclusions about something. Japanese often prefer to use business meetings as a place to report findings only. Suspend that tendency and show willingness to review and discuss challenges. Try and give feedback-even if the product is not exactly what you are looking for. Experiment with alternatives. Remember agile environments welcome changing requirements, even late in development. You may find (ultimately) that your expectations have been exceeded.
Leverage one of the most important relationships in Japanese social context (the revered senpai-kohai relationship) and find a good mentor. Japanese pharma companies are good at developing (or acquiring) drugs, but software isn’t necessarily their forte. Why not get your preferred reseller involved? Having a trusted expert who can translate business requirements into everyday language may eliminate an unnecessary steep learning curve.
Japanese life sciences firms are making an important shift, moving from the role of partner in the clinical research value chain to an integral part of a global study team. As we make that shift, executives will need to do more to “think locally” when designing trials, carefully accounting for regional and cultural differences along the way. Though many study risk assessments already account for regional differences in infrastructure, resources, and patient availability, few go deep enough to consider how culture in a given region may impact issues such as patient enrollment, compliance, and investigator engagement.
The deep cultural differences between the US and Japan in the clinical research context bring home the need to collaborate closely and ensure there is a strong two-way information flow between global, regional, and local teams. They also highlight the importance of staying close to investigators and technology providers, while respecting differences in the various ways of working. With the future of drug development relying more and more on multinational clinical trials and simultaneous submission to the major regulatory authorities, this is a timely and pertinent topic that warrants serious thought and consideration.
Jae Chung is the Founder and President of goBalto, email: email@example.com; Masashi Kiyomine is Investment Director at Mitsui Global Investment, email: M.Kiyomine@mitsui.com
1. Takabayashi K, Doi S, Suzuki T. Japanese EMRs and IT in Medicine: Expansion, Integration, and Reuse of Data. Healthcare Informatics Research. 2011;17(3):178-183. doi:10.4258/hir.2011.17.3.178.
2. Cox Gad, Shayne. The Clinical Trial Handbook. John Wiley & Sons, June 17, 2009. pp 762-765.
3. Conducting Clinical Trials in Japan: A CRO Perspective (2013). Available at https://www.ppdi.com/~/media/Files/PPDI%20Files/Expert%20Community/Whitepapers/Clinical-Trials-Japan-PPD-White-Paper.ashx.
4. Nishino, Junichi. Overcoming Regulatory Hurdles in Running Clinical Trials in Japan. Novartis Pharma K.K. Global Clinical Trials Outsourcing Summit (presentation). Seoul, Korea; May 20, 2013. Available at: http://www.globalengage.co.uk/gctos/6Nishino.pdf.